Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial

Sirolimus (SRL) has been reported to benefit patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). This study aimed to compare SRL with tacrolimus (TAC) in living-donor LT (LDLT) recipients beyond the Milan criteria. This study was initially designed to enrol 45 recipien...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Med
Main Authors: Lee, Kwang-Woong, Kim, Seong Hoon, Yoon, Kyung Chul, Lee, Jeong-Moo, Cho, Jae-Hyung, Hong, Suk Kyun, Yi, Nam-Joon, Han, Sung-Sik, Park, Sang-Jae, Suh, Kyung-Suk
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7600292/
https://ncbi.nlm.nih.gov/pubmed/33053849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9103264
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki